← Back to headlines
SK Biopharmaceuticals Licenses Epilepsy Drug Candidate from Biohaven
SK Biopharmaceuticals has signed a licensing deal with US firm Biohaven for an epilepsy drug candidate. This agreement grants SK Biopharmaceuticals rights to the experimental treatment.
Sources
Showing 0 of 2 sources
No articles available in your preferred languages.
2 articles available in other languages below.
investing-comDanish4h ago
SK Biopharmaceuticals signs epilepsy drug licensing deal with Biohaven
Read full article →yonhap-englishRomanian5h ago
SK Biopharm buys license for epilepsy drug candidate from U.S. firm
SEOUL, Aug. 26 (Yonhap) -- SK Biopharmaceuticals Co., a pharmaceutical affiliat...
Read full article →Coverage Timeline
First report: yonhap-english · 26 Aug, 03:08|Full coverage: 2 · 57m|Window: 57m
Left-leaningCenterRight-leaning
